It also points to the need for better strategies to make these treatments more accessible and available to those who need them. Prior to this research, a small study of 106 postmenopausal women published in 2024 in the medical journal Menopause found that those who were on both MHT and the GLP-1 drug semaglutide had lost about 16 percent of their total body weight after a year, compared to 12 percent for women on a GLP-1 alone
That kind of weight loss can lead to other health improvements like lowered blood pressure, blood sugar, and some blood fats, and can improve joint pain and sleep apnea
More people today are paying attention to whats happening inside their bodies and how it reflects on their skin
GLP-1 medications are intriguing from a cancer research perspective because they werent designed for cancer therapy, but they do affect many different targets and pathways associated with cancer development, so were eager to study them in this context, McDonald says
The new approval reinforces Krazatis potential across tumor types, the company said in a press release
